Amine Linked Flavonoid Dimers as Modulators for P-Glycoprotein-Based Multidrug Resistance: Structure-Activity Relationship and Mechanism of Modulation

被引:68
作者
Chan, Kin-Fai [1 ,2 ]
Wong, Iris L. K. [1 ,2 ]
Kan, Jason W. Y. [1 ,2 ]
Yan, Clare S. W. [1 ,2 ]
Chow, Larry M. C. [1 ,2 ]
Chan, Tak Hang [1 ,2 ,3 ]
机构
[1] Hong Kong Polytech Univ, State Key Lab Chirosci, Dept Appl Biol & Chem Technol, Hong Kong, Hong Kong, Peoples R China
[2] Hong Kong Polytech Univ, State Key Lab Chinese Med & Mol Pharmacol, Shenzhen, Peoples R China
[3] McGill Univ, Dept Chem, Montreal, PQ H3A 2K6, Canada
关键词
HUMAN BREAST-CANCER; CYCLOSPORINE-A; BIVALENT MODULATORS; CELL-LINE; IN-VITRO; DAUNORUBICIN RESISTANCE; VINCRISTINE RESISTANCE; CALMODULIN INHIBITORS; APIGENIN HOMODIMERS; CALCIUM-ANTAGONISTS;
D O I
10.1021/jm201121b
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Here we report a great improvement in reversal potency of cancer drug resistance when flavonoid dimers possess a functionally substituted aminopolyethylene glycol linker. The most potent compound, 18, contains a N-benzyl group at the linker. It has many advantages including (1) high potencies in reversing P-glycoprotein (P-gp) mediated resistance in LCC6MDR cells to various anticancer drugs with EC50 in the nanomolar range, (2) low toxicity and high therapeutic index, and (3) preferential inhibition of P-gp over multidrug resistance protein 1 and breast cancer resistance protein. Compound 18 stimulates P-gp-ATPase activity by 2.7-fold and mediates a dose-dependent inhibition of doxorubicin (DOX) transport activity. Lineweaver-Burk and Dixon plots suggest that 18 is a competitive inhibitor to DOX in binding to P-gp with a K-i of 0.28-0.34 mu M and a Hill coefficient of 1.17. Moreover, the LCC6MDR cell displays about 2.1-fold lower intracellular accumulation of 18 compared to the wild type, suggesting that 18 is a P-gp substrate as well.
引用
收藏
页码:1999 / 2014
页数:16
相关论文
共 51 条
  • [11] EFFECTS OF FLAVONOLS ON P-GLYCOPROTEIN ACTIVITY IN CULTURED RAT HEPATOCYTES
    CHIELI, E
    ROMITI, N
    CERVELLI, F
    TONGIANI, R
    [J]. LIFE SCIENCES, 1995, 57 (19) : 1741 - 1751
  • [12] C-isoprenylation of flavonoids enhances binding affinity toward P-glycoprotein and modulation of cancer cell chemoresistance
    Comte, G
    Daskiewicz, JB
    Bayet, C
    Conseil, G
    Viornery-Vanier, A
    Dumontet, C
    Di Pietro, A
    Barron, D
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (05) : 763 - 768
  • [13] MODULATION OF ADRIAMYCIN(R) ACCUMULATION AND EFFLUX BY FLAVONOIDS IN HCT-15 COLON CELLS - ACTIVATION OF P-GLYCOPROTEIN AS A PUTATIVE MECHANISM
    CRITCHFIELD, JW
    WELSH, CJ
    PHANG, JM
    YEH, GC
    [J]. BIOCHEMICAL PHARMACOLOGY, 1994, 48 (07) : 1437 - 1445
  • [14] CORRELATION BETWEEN POTENCY OF CALMODULIN INHIBITORS AND EFFECTS ON CELLULAR-LEVELS AND CYTO-TOXIC ACTIVITY OF DOXORUBICIN (ADRIAMYCIN) IN RESISTANT P388 MOUSE LEUKEMIA-CELLS
    GANAPATHI, R
    GRABOWSKI, D
    TURINIC, R
    VALENZUELA, R
    [J]. EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1984, 20 (06): : 799 - 806
  • [15] Cellular and biochemical characterization of VX-710 as a chemosensitizer: Reversal of P-glycoprotein-mediated multidrug resistance in vitro
    Germann, UA
    Shlyakhter, D
    Mason, VS
    Zelle, RE
    Duffy, JP
    Galullo, V
    Armistead, DM
    Saunders, JO
    Boger, J
    Harding, MW
    [J]. ANTI-CANCER DRUGS, 1997, 8 (02) : 125 - 140
  • [16] P-glycoprotein - A mediator of multidrug resistance in tumour cells
    Germann, UA
    [J]. EUROPEAN JOURNAL OF CANCER, 1996, 32A (06) : 927 - 944
  • [17] Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP
    Germann, UA
    Ford, PJ
    Shlyakhter, D
    Mason, VS
    Harding, MW
    [J]. ANTI-CANCER DRUGS, 1997, 8 (02) : 141 - 155
  • [18] GRUOL DJ, 1994, CANCER RES, V54, P3088
  • [19] Harborne J B, 1986, Prog Clin Biol Res, V213, P15
  • [20] REVERSAL OF MULTIDRUG RESISTANCE BY B859-35, A METABOLITE OF B859-35, NIGULDIPINE, VERAPAMIL AND NITRENDIPINE
    HOFMANN, J
    WOLF, A
    SPITALER, M
    BOCK, G
    DRACH, J
    LUDESCHER, C
    GRUNICKE, H
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1992, 118 (05) : 361 - 366